A Phase 3 interventional study of sumatriptan succinate / naproxen sodium and Placebo in Migraine, Without Aura, sponsored by GlaxoSmithKline. Completed at 70 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Migraine without Aura with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Migraine without Aura · United States.
Among the 31 studies in Migraine without Aura with a site in United States, this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
109 studies on the registry are indexed under Migraine without Aura; 17 are open to participants now.
Browse Migraine without Aura studies →5 of the 31 studies in Migraine without Aura with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Evommune, Inc. · Sites in United States, Australia, Canada and 1 more country
Ages 18–64
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 10–17
Brigham and Women's Hospital · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Migraine without Aura studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 679 is above the median of 87 across 87 interventional studies indexed under Migraine without Aura.
Median enrollment 96 across the 30 interventional studies. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 31 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
GlaxoSmithKline has 1 study filed under Migraine without Aura — fewer than ten, so there is no comparison to draw.
4 of the studies in Migraine without Aura with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987592Wake Forest University Health SciencesBE WELL With Migraine: Brain Education and WELLness With Migraine | 2027-06-30 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
| NCT05889624Children's Hospital Medical Center, CincinnatiResponding With Evidence and Access for Childhood Headaches | 2027-07-31 |
| NCT07616128Evommune, Inc.Study of EVO756 in Adults With Migraine | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Migraine without Aura with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: sumatriptan succinate / naproxen sodium
Drug pages: SumatriptanStudies of SumatriptanSumatriptan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
sumatriptan 85mg / naproxen sodium 500mg
Placebo to match Treximet tablets
Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.
Pain-free was defined as a headache severity of no pain (grade 0) at 2 hours post-treatment in subjects who have not used rescue medication prior to or at the time of the assessment. Sustained pain-free response was defined as pain-free at 2 hours post-treatment through 24 hours post-treatment without rescue medicine.
Time frame: 2 hours through 24 hours after Treatment
Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment
Pain-Free is defined as post-treatment headache pain severity of none in subjects who have not used rescue medication prior to or at the time of the assessment.
Time frame: 0.5, 1, and 4 hours after Treatment
Sustained Headache Relief 2-24 Hours After Treatment
Sustained pain relief was defined as having pain relief (mild or no pain) at 2 hours w/o any moderate or severe pain during 2-24 hour period post-treatment, without rescue medication.
Time frame: 2-24 hours after treatment
Headache Relief at 4, 2, 1 and 0.5 Hours After Treatment
Pain relief was defined as reduction of headache pain from a baseline severity of moderate or severe to none or mild at the given time.
Time frame: 0.5, 1, 2, and 4 hours after treatment
Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment
Rescue medication defined as additional medication (i.e. sumatriptan/naproxen sodium as open-label rescue or other medication as permitted per protocol), taken by subject for the treatment of headache pain or other symptoms associated with the headache attack.
Time frame: 0 - 24 hours after treatment
Intermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment
Intermediate sustained pain relief was defined as achieving headache pain relief (from moderate or severe pain at baseline to mild or no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours). (Intermediate=Intermed.)
Time frame: 1-2, and 2- 4 hours after treatment
Intermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours
Intermediate sustained pain free was defined as achieving headache pain-free (moderate or severe pain to no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours).(Intermediate=Intermed.)
Time frame: 1-2 and 2-4 hours after treatment
Incidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment
Neck pain, sinus pain, photophobia, phonophobia and nausea are considered headache-associated symptoms.(Headache-associated=Headache-Assoc.)
Time frame: 2 and 4 hours after treatment
Medication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score
Patient Perception of Migraine Questionnaire-Revised(PPMQ-R) evaluates subject satisfaction with treatment 24 hours post-dose using validated questions. Questions are analyzed on 4 subscale scores (efficacy, functionality, ease-of-use, and tolerability) and total score. Scores range from 0-100, with the higher scores indicating better satisfaction.
Time frame: 0 - 24 hours after treatment
| Milestone | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Started | 334 | 345 |
| Completed | 245 | 243 |
| Not completed | 89 | 102 |
| Withdrew: Lost to follow-up | 23 | 23 |
| Withdrew: Protocol violation | 2 | 12 |
| Withdrew: Withdrawal by subject | 15 | 18 |
| Withdrew: Sponsor terminated study | 0 | 1 |
| Withdrew: Not eligible | 6 | 7 |
| Withdrew: No opportunity to treat headache | 32 | 34 |
| Withdrew: Not otherwise specified | 11 | 7 |
Pain-free was defined as a headache severity of no pain (grade 0) at 2 hours post-treatment in subjects who have not used rescue medication prior to or at the time of the assessment. Sustained pain-free response was defined as pain-free at 2 hours post-treatment through 24 hours post-treatment without rescue medicine.
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Pain-Free (2 hours) | 25 | 64 |
| Sustained Pain-Free (2-24 hours) | 20 | 54 |
Pain-Free is defined as post-treatment headache pain severity of none in subjects who have not used rescue medication prior to or at the time of the assessment.
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Pain-free at 4 hours | 60 | 105 |
| Pain-free at 1 hour | 16 | 23 |
| Pain-free at 0.5 hour | 6 | 5 |
Sustained pain relief was defined as having pain relief (mild or no pain) at 2 hours w/o any moderate or severe pain during 2-24 hour period post-treatment, without rescue medication.
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Sustained Headache Relief 2-24 Hours After Treatment | 77 | 110 |
Pain relief was defined as reduction of headache pain from a baseline severity of moderate or severe to none or mild at the given time.
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Headache relief at 4 hours | 108 | 153 |
| Headache relief at 2 hours | 113 | 124 |
| Headache relief at 1 hour | 73 | 85 |
| Headache relief at 0.5 hour | 39 | 41 |
Rescue medication defined as additional medication (i.e. sumatriptan/naproxen sodium as open-label rescue or other medication as permitted per protocol), taken by subject for the treatment of headache pain or other symptoms associated with the headache attack.
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment | 101 | 61 |
Intermediate sustained pain relief was defined as achieving headache pain relief (from moderate or severe pain at baseline to mild or no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours). (Intermediate=Intermed.)
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Intermed. Sustained Pain Relief, 2-4 hrs post-dose | 92 | 118 |
| Intermed. Sustained Pain Relief, 1-2 hrs post-dose | 67 | 84 |
Intermediate sustained pain free was defined as achieving headache pain-free (moderate or severe pain to no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours).(Intermediate=Intermed.)
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Intermed. Sustained Pain-free, 2-4 hrs post-dose | 22 | 61 |
| Intermed. Sustained Pain-free, 1-2 hrs post-dose | 11 | 23 |
Neck pain, sinus pain, photophobia, phonophobia and nausea are considered headache-associated symptoms.(Headache-associated=Headache-Assoc.)
| Participants | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Headache-Assoc. Neck Pain at 4 hours | 93 | 63 |
| Headache-Assoc. Neck Pain at 2 hours | 68 | 59 |
| Headache-Assoc. Sinus Pain at 4 hours | 88 | 49 |
| Headache-Assoc. Sinus Pain at 2 hours | 49 | 36 |
| Headache-Assoc. Photophobia at 4 hours | 87 | 60 |
| Headache-Assoc. Photophobia at 2 hours | 60 | 46 |
| Headache-Assoc. Phonophobia at 4 hours | 83 | 59 |
| Headache-Assoc. Phonophobia at 2 hours | 53 | 54 |
| Headache-Assoc. Nausea at 4 hours | 82 | 51 |
| Headache-Assoc. Nausea at 2 hours | 37 | 36 |
Patient Perception of Migraine Questionnaire-Revised(PPMQ-R) evaluates subject satisfaction with treatment 24 hours post-dose using validated questions. Questions are analyzed on 4 subscale scores (efficacy, functionality, ease-of-use, and tolerability) and total score. Scores range from 0-100, with the higher scores indicating better satisfaction.
| Score in scale | Placebo | Sumatriptan/Naproxen |
|---|---|---|
| Efficacy Adjusted Mean | 53 ± 2.0 | 67 ± 2.0 |
| Functionality Adjusted Mean | 56 ± 2.1 | 70 ± 2.1 |
| Ease-of-Use Adjusted Mean | 84 ± 1.3 | 88 ± 1.3 |
| Bothersome-of-Side Effects Adjusted Mean | 94 ± 0.8 | 91 ± 0.8 |
| Total Score adjusted Mean | 64 ± 1.5 | 75 ± 1.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/246 (0%) | 0/246 (0%) |
| Sumatriptan/Naproxen | — | 0/254 (0%) | 0/254 (0%) |
| Age, Continuous(years) | Placebo | Sumatriptan/Naproxen | Total |
|---|---|---|---|
| Mean | 36.6 ± 11.23 | 35.8 ± 11.47 | 36.2 ± 11.35 |
| Gender(Participants) | Placebo | Sumatriptan/Naproxen | Total |
|---|---|---|---|
| Female | 176 | 195 | 371 |
| Male | 70 | 59 | 129 |
| Race/Ethnicity, Customized(Participants) | Placebo | Sumatriptan/Naproxen | Total |
|---|---|---|---|
| African American/African Heritage | 28 | 30 | 58 |
| American Indian or Alaskan Native | 1 | 0 | 1 |
| Asian - East Asian Heritage | 6 | 8 | 14 |
| Asian - Japanese Heritage | 2 | 1 | 3 |
| Asian - South East Asian Heritage | 8 | 5 | 13 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| White - Arabic/North African Heritage | 1 | 2 | 3 |
| White - White/Caucasian/European Heritage | 199 | 206 | 405 |
| Mixed race | 0 | 1 | 1 |
| Missing | 0 | 1 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sumatriptan · Naproxen